CompoAtlas

NOCICEPTOL CIRCULATION & JAMBES LEGERES

Integratore alimentare dichiarato in Francia, notifica n. 2022-9-956, decisione del 13 settembre 2022

NOCICEPTOL CIRCULATION & JAMBES LEGERES, dell'azienda LABORATOIRE POLIDIS, è un integratore alimentare dichiarato in Francia. Stato: dichiarato in Francia, commercializzazione possibile. Ingredienti principali: Hibiscus sabdariffa 1.500 mg al giorno, Vitis vinifera 42 mg al giorno, Ribes nigrum 40 mg al giorno, Hamamelis virginiana 30 mg al giorno, Crataegus laevigata 20 mg al giorno. Nessuna delle regole che verifichiamo rileva punti sulla composizione dichiarata.

Marca
NOCICEPTOL
Responsabile dell’immissione in commercio
LABORATOIRE POLIDIS
Stato
Dichiarato in Francia, commercializzazione possibile: l’amministrazione non si è opposta alla dichiarazione (non è né un’autorizzazione né una valutazione della sicurezza)
Forma
Compressa
Dose giornaliera

1

Popolazioni destinatarie
Donne in gravidanza, Donne che allattano, Uomini, Donne
Sconsigliato (secondo il fabbricante)
Adolescenti (sotto i 18 anni), Bambini (sotto i 12 anni)

Notifica 269036, procedura Article 15. Compl’Alim, dichiarazioni di integratori alimentari, consultato il 15 novembre 2026.

Composizione dichiarata

Piante

PiantaPartePreparazioneAl giorno
Hibiscus sabdariffa L.FleurExtrait sec aqueux1.500 mg
Vitis vinifera L.FeuillePoudre (de plantes séchées ou broyées)42 mg
Ribes nigrum L.FeuilleExtrait sec aqueux40 mg
Hamamelis virginiana L.FeuilleExtrait sec aqueux30 mg
Crataegus laevigata (Poir.) DC.Sommités fleuriesPoudre (de plantes séchées ou broyées)20 mg
Syzygium aromaticum (L.) Merr. & L.M.PerryBouton floralPoudre (de plantes séchées ou broyées)20 mg
Tanacetum parthenium (L.) Sch.Bip.Parties aériennesExtrait sec hydroalcoolique20 mg
Vaccinium myrtillus L.FruitPoudre (de plantes séchées ou broyées)20 mg
Chrysanthellum indicum subsp. afroamericanum B.L.TurnerParties aériennesPoudre (de plantes séchées ou broyées)19 mg
Melissa officinalis L.FeuilleExtrait sec aqueux18 mg
Cupressus sempervirens L.Cône femellePoudre (de plantes séchées ou broyées)17 mg
Centella asiatica (L.) Urb.Parties aériennesExtrait sec aqueux13 mg
Sedum roseum (L.) Scop.RacineExtrait sec hydroalcoolique11 mg
Eleutherococcus senticosus (Rupr. et Maxim.) MaximRacineExtrait sec aqueux10 mg
Ganoderma lucidum(Curtis ex Fr.) P.Karst.CarpophoreExtrait sec hydroalcoolique10 mg

Additivi

E414, E341, E470b

Elenco della dichiarazione, decisione dell'amministrazione del (Compl’Alim, dichiarazioni di integratori alimentari).

Fotografare la confezione

Avvertenze dell’etichetta

Testo originale in francese.

Les compléments alimentaires doivent être utilisés dans le cadre d’un mode de vie sain et ne se substituent pas à une alimentation variée et équilibrée. Réservé à l’adulte. Ne pas dépasser la dose journalière recommandée. Tenir hors de portée des jeunes enfants. Conserver à l’abri de la chaleur et de l’humidité. Ne pas dépasser la date limite d’utilisation.

Compl’Alim, dichiarazioni di integratori alimentari ·

Aspetti normativi

Nessuna delle norme che verifichiamo si applica agli ingredienti notificati.

Queste informazioni riprendono la dichiarazione del fabbricante all’amministrazione (DGAL). Non dicono se il prodotto sia efficace e non sostituiscono il parere di un medico o farmacista, in particolare in gravidanza o durante un trattamento.

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

  • Hamamelis virginiana L.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    WITCH HAZEL - HAMAMELIS VIRGINIANA Buccal and Oromucosal

    Via di somministrazione: Buccal Oromucosal

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 27 febbraio 2026

    WITCH HAZEL - HAMAMELIS VIRGINIANA Ophthalmic

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or persist (for) more than 2 days (EMA 2009).

    Fonti citate da Health Canada (1)
    • EMA 2009: European Medicines Agency. Committee on Herbal Medicinal Products. Community Herbal Monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatium. [Accessed 2026 February 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience eye pain, changes in vision, continued redness, or irritation of the eye (EMA 2009).

    Fonti citate da Health Canada (1)
    • EMA 2009: European Medicines Agency. Committee on Herbal Medicinal Products. Community Herbal Monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatium. [Accessed 2026 February 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf

    Monografia di Health Canada del 27 febbraio 2026

    WITCH HAZEL -HAMAMELIS VIRGINIANA Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    Fonti citate da Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Reazioni avverse note

    When using this product you may experience gastrointestinal discomfort/disturbances (Gardner and McGuffin 2013; ESCOP 2003; Berardi et al. 2002; Mills and Bone 2000).

    Fonti citate da Health Canada (4)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.

    Monografia di Health Canada del 27 febbraio 2026

    WITCH HAZEL - HAMAMELIS VIRGINIANA Topical

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Si applica ai prodotti: for use on minor wounds/burns/bruises/irritations/inflammations or on hemorrhoids.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen, last (for) more than 7 days.

    Si applica ai prodotti: for use on varicose veins.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Controindicazioni

    Si applica ai prodotti: for use on minor wounds/burns/bruises/irritations/inflammations.

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Reazioni avverse note

    Condizione di applicazione: All products.

    Stop use if a skin rash occurs (ESCOP 2003; Berardi et al. 2002; Mills and Bone 2000).

    Fonti citate da Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Si applica ai prodotti: for use on hemorrhoids.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience bleeding.

    Monografia di Health Canada del 27 febbraio 2026

  • Crataegus laevigata (Poir.) DC.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    Hawthorn

    Via di somministrazione: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).

    Fonti citate da Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.

    Monografia di Health Canada del 31 luglio 2026

  • Tanacetum parthenium (L.) Sch.Bip.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    FEVERFEW - TANACETUM PARTHENIUM

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).

    Fonti citate da Health Canada (2)
    • Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;320(8301):776. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Si applica ai prodotti: providing 250 mg or less of dried herb top and/or leaf, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).

    Fonti citate da Health Canada (1)
    • Boon H. Feverfew. In: Chandler F, editor. Herbs: Everyday Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association and the Canadian Medical Association; 2000.

    Controindicazioni

    Si applica ai prodotti: providing 250 mg or less of dried herb top and/or leaf, per day.

    Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).

    Fonti citate da Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Si applica ai prodotti: providing more than 250 mg of dried herb top and/or leaf, per day.

    Do not use if you are pregnant or breastfeeding (EMA 2020).

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Reazioni avverse note

    Condizione di applicazione: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).

    Fonti citate da Health Canada (2)
    • Hausen BM. A 6-year experience with compositae mix. American Journal of Contact Dermatitis 1996;7(2):94-99. PubMed
    • Paulsen E, Anderson KE and Hausen BM. Sensitization and cross-reaction patterns in Danish Compositae-allergic patients. Contact Dermatitis 2001;45(4):197-204. PubMed

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).

    Fonti citate da Health Canada (3)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Johnson ES, Kadam NP, Hylands DM, Hylands PJ. 1985. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal 291(6495):569-573.
    • Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;332(8604):189-192.

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Monografia di Health Canada del 19 dicembre 2025

  • Vaccinium myrtillus L.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    BILBERRY - VACCINIUM MYRTILLUS - Buccal

    Via di somministrazione: Buccal (Blumenthal et al. 2000)

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 30 gennaio 2026

    BILBERRY - VACCINIUM MYRTILLUS - Oral

    Via di somministrazione: Oral (Blumenthal et al. 2000)

    Precauzioni e avvertenze

    Condizione di applicazione: Relief of diarrhea.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condizione di applicazione: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Monografia di Health Canada del 25 ottobre 2024

  • Melissa officinalis L.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    LEMON BALM -MELISSA OFFICINALIS

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    Fonti citate da Health Canada (1)
    • EMA 2014. European Medicines Agency. Melissae folium.. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 16 June2014. [Accessed 2023 October 27]. Available at: https://www.ema.europa.eu/en/medicines/herbal/melissae-folium

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    Fonti citate da Health Canada (1)
    • EMA 2014. European Medicines Agency. Melissae folium.. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 16 June2014. [Accessed 2023 October 27]. Available at: https://www.ema.europa.eu/en/medicines/herbal/melissae-folium

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 26 aprile 2024

  • Sedum roseum (L.) Scop.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    RHODIOLA - RHODIOLA ROSEA

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Fonti citate da Health Canada (1)
    • EMA 2024: 20 March 2024 EMA/HMPC/24177/2023 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Rhodiola rosea L., rhizoma et radix Final - Revision 1. Amsterdam (NL): European Medicines Agency, Science Medicines Health. [Accessed 2025 January 21]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rhodiola-rosea-l-rhizoma-et-radix-revision-1_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, hormone replacement therapy (HRT) or birth control medication (HC 2018; Iovieno et al. 2011; Olsson et al. 2009; Brown et al. 2002).

    Fonti citate da Health Canada (4)
    • Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: A Phytomedicinal Overview. HerbalGram 2002;56:40-52.
    • HC 2018: Health Canada. Canada Vigilance Adverse Reaction Online Database. Ottawa (ON): Marketed Health Products Directorate, Health Canada. [Accessed 2025 January 21]. Available from: https://cvp-pcv.hc-sc.gc.ca/arq-rei/index-eng.jsp
    • Iovieno, N., Dalton, ED., Fava, M., Mischoulon, D. Second-tier natural antidepressants: review and critique. Journal of Affective Disorders 2011;130(3): 343-357.
    • SC 2018: Santé Canada. Base de données en ligne des effets indésirables de Canada Vigilance. Ottawa (ON): Direction des produits de santé commercialisés, Santé Canada. [Consulté le 21 janvier 2025]. Disponible à : https://cvp-pcv.hc-sc.gc.ca/arq-rei/switchlocale.do?lang=fr&url=t.search.recherche

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Controindicazioni

    Do not use if you have bipolar disorder or bipolar spectrum disorder (Iovieno et al. 2011; Winston and Maimes 2007; Brown et al. 2002).

    Fonti citate da Health Canada (3)
    • Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: A Phytomedicinal Overview. HerbalGram 2002;56:40-52.
    • Iovieno, N., Dalton, ED., Fava, M., Mischoulon, D. Second-tier natural antidepressants: review and critique. Journal of Affective Disorders 2011;130(3): 343-357.
    • Winston D, Maimes S. Adaptogens: Herbs for Strength, Stamina, and Stress Relief. Rochester (VT): Healing Arts Press, 2007.

    Reazioni avverse note

    Stop use if you experience irritability or insomnia (Pizzorno and Murray 2006; Kelly 2001).

    Fonti citate da Health Canada (2)
    • Kelly GS. Rhodiola rosea: A Possible Plant Adaptogen. Alternative Medicine Review 2001;6(3): 293-302. PubMed Articolo di revisione
    • Pizzorno JE, Murray MT, editors. Textbook of Natural Medicine. 3rd edition, volume 1. St. Louis (MI): Churchill Livingstone Elsevier; 2006.

    Monografia di Health Canada del 31 ottobre 2025

  • Eleutherococcus senticosus (Rupr. et Maxim.) Maxim
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS

    Via di somministrazione: Oral (ESCOP 2003; Bradley 1992)

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    Fonti citate da Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).

    Fonti citate da Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Controindicazioni

    Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).

    Fonti citate da Health Canada (5)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Monografia di Health Canada del 31 ottobre 2025

Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.

Marca : NOCICEPTOL

Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.

Elenco rilevato nel 2022. Fotografi la confezione per verificare eventuali modifiche.

Invio per analizzare, Maiusc+Invio per una nuova riga